Aktis Oncology, Inc. (AKTS)

Healthcare · Biotechnology · Small-cap · updated October 16, 2026

NOT A BUY TODAY

What this means. Aktis Oncology, Inc. is an average business by our measures, its shares look fairly priced, and its share price has been weak.

Value45

Quality48

Price trend4

Overall38

2451 of 2764rank among the US stocks we score (our core model buys the top 15)

11%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

Insider trades, last 90 days

1 insider sold $119K on the open market.

Herrmann KenDirector

SoldJul 20

4,856 shat $24.56 · $119K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

XERS Xeris Biopharma Holdings, Inc.overall 73 · rank 16
INVA Innoviva, Inc.overall 69 · rank 57
CRMD CorMedix Inc.overall 68 · rank 78
NRIX Nurix Therapeutics, Inc.overall 68 · rank 79
RIGL Rigel Pharmaceuticals, Inc.overall 68 · rank 81

Interactive lookup Get the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy